Protection of ovarian function by GnRH agonists during chemotherapy: A meta-analysis

Sun,Xiaomei; Dongol,Samina; Jiang,Jie; Kong,Beihua

doi:10.3892/ijo.2014.2296

Protection of ovarian function by GnRH agonists during chemotherapy: A meta-analysis

Authors:
- Xiaomei Sun
- Samina Dongol
- Jie Jiang
- Beihua Kong
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan 250012, P.R. China
Published online on: February 11, 2014 https://doi.org/10.3892/ijo.2014.2296
Pages: 1335-1340

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This meta-analysis was designed to assess the overall performance of GnRHa in preserving the ovarian function in young women undergoing chemotherapy. Electronic literature databases including Pubmed, MEDLINE, Cochrane library, Embase, CNKI and Wanfang were searched for articles published till November, 2013. The articles written in both Chinese and English were considered. Only randomized controlled trials (RCTs) were selected. Main Outcome Measure was evaluated by assessing the post‑chemotherapy ovarian function. A random-effects model was used to calculate the risk ratio (RR) and associated 95% confidence intervals (95% CI). Out of the eight RCTs including 621 patients, 321 women were treated with GnRHa during chemotherapy, 9.66% of whom suffered premature ovarian failure (POF). On the other hand, 26.67% of the remaining 300 women suffered POF. More women treated without GnRHa experienced post-chemotherapy POF, yielding an RR of 0.45 [chemotherapy plus GnRHa vs. chemotherapy alone, 95% confidence interval (CI) (0.22, 0.92)]. Based on the available studies, GnRHa plays an important role in the prevention of post-chemotherapy POF, but does not exhibit its protective effects in fertility.

View Figures

View References

1.	Surveillance, Epidemiology and End Results (SEER) Web site: Available online: http://www.seer.cancer.govApril2010 based on the November 2009 submission.
2.	Beck-Peccoz P and Persani L: Premature ovarian failure. Orphanet J Rare Dis. 1:92006. View Article : Google Scholar
3.	Sonmezer M and Oktay K: Fertility preservation in female patients. Hum Reprod Update. 10:251–266. 2004. View Article : Google Scholar
4.	Bokser L, Szende B and Schally AV: Protective effects of D-Trp6-luteinizing hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer. 61:861–865. 1990. View Article : Google Scholar
5.	Ataya K, Rao LV, Lawrence E and Kimmel R: Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depeletion in rhesus monkeys. Biol Reprod. 52:365–372. 1995. View Article : Google Scholar
6.	Del Mastro L, Catzeddu T, Boni L, et al: Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol. 17:74–78. 2006.PubMed/NCBI
7.	Clowse ME, Behera MA, Anders CK, Copland S, et al: Ovarian preservation by GnRH agonists during chemotherapy: A meta-analysis. J Women’s Health. 18:311–319. 2009.PubMed/NCBI
8.	Yang B, Shi W, Yang J, Liu H, Zhao H, et al: Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: A meta-analysis of randomized controlled trials. Breast. 22:150–157. 2013. View Article : Google Scholar
9.	Turner NH, Partridge A, Sanna G, Di Leo A and Biganzoli L: Utility of gonadotropin-releasing hormone agonists forfertility preservation in young breast cancer patients: the benefit remains uncertain. Ann Oncol. 24:2224–2235. 2013. View Article : Google Scholar : PubMed/NCBI
10.	Higgins JPT and Green S: Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cohran Collaboration (updated March 2011).
11.	Badawy A, Elnashar A, El-Ashry M and Shahat M: Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 91:694–697. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Munster PN, Moore AP, et al: Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 30:533–538. 2012. View Article : Google Scholar
13.	Waxman JH, Ahmed R, Smith D, Wrigley PEM, et al: Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol. 19:159–162. 1987.
14.	Loverro G, Guarini A, Di Naro E, et al: Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology. 12:141–147. 2007. View Article : Google Scholar : PubMed/NCBI
15.	Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, et al: Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 306:269–276. 2011.
16.	Elgindy EA, El-Haieg DO, Khorshid OM, et al: Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol. 121:78–86. 2013.PubMed/NCBI
17.	Gerber B, von Minlkwitz G, Stehle H, Reimer T, et al: Effect of luteining hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer therapy: The GBG 37 ZORO study. J Clin Oncol. 29:2334–2341. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Gilani MM, Hasanzadeh M, Ghaemmaghami F, et al: Ovarian preservation with gonadotrop in releasing hormone analog during chemotherapy. Asia Pac J Clin Oncol. 3:79–83. 2007. View Article : Google Scholar
19.	Blumenfeld Z: How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embryo, oocytes, or ovaries. Oncologist. 12:1044–1054. 2007. View Article : Google Scholar : PubMed/NCBI
20.	Goswami D and Conway GS: Premature ovarian failure. Hum Reprod Update. 11:391–410. 2005. View Article : Google Scholar
21.	Ravdin PM, Fritz NF, Tormey DC and Jordan VC: Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res. 48:1026–1029. 1989.PubMed/NCBI
22.	Anderson RA, Themmen AP, Al-Qahtani A, Groome NP and Cameron DA: The effects of chemotherapy and long-term gonadotropin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod. 21:2583–2592. 2006. View Article : Google Scholar : PubMed/NCBI
23.	Sverrisdottir A, Nystedt M, Johansson H and Fornander T: Adjuvant goserelin and ovarian preservation in chemotherapytreated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat. 117:561–567. 2009. View Article : Google Scholar : PubMed/NCBI
24.	Partridge A, Gelber S, Gerber RD and Castiglione-Certsch M: Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer. 43:1646–1653. 2007. View Article : Google Scholar
25.	Te Velde ER and Pearson PL: The variability of female reproductive ageing. Hum Reprod Upadate. 8:141–154. 2002.PubMed/NCBI